Global generic and specialist pharmaceuticals company Mylan has won a US District Court Ruling with regards to its Copaxone 40mg/mL patents.

The court for the District of Delaware issued a decision finding all asserted claims of four of the company’s Orange Book-listed patents relating to Copaxone invalid based on obviousness.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The invalidated US Patent Numbers 8,232,250; 8,399,413; 8,969,302; and 9,155,776 are owned by Yeda Research & Development and licensed to Teva Pharmaceuticals.

Mylan CEO Heather Bresch said: "Today's ruling by the US District Court is yet another positive step in our effort to bring to market a more affordable generic version of Copaxone 40mg/mL.

“We will continue to challenge the validity of patents as a way to expedite the availability of generic drugs and help deliver access and savings to patients and the overall healthcare system."

See Also:

"Today's ruling by the US District Court is yet another positive step in our effort to bring to market a more affordable generic version of Copaxone 40mg/mL."

The US Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) reaffirmed a prior decision on 2 December last year that the 250, 413 and 302 patents are unpatentable in its inter partes review (IPR) proceedings initiated by Mylan.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company also challenged the 776 patent in an IPR proceeding.

The institution ruling by PTAB is expected to be issued on the '776 patent IPR by 16 May this year.

Mylan stated that it has filed a complete abbreviated new drug application for a three times per week Glatiramer Acetate Injection 40mg/mL.

According to IMS Health, Copaxone had sales in the US of approximately $3.3bn for the 12 months ending 30 November last year.

Mylan offers a portfolio of more than 2,700 generic and branded pharmaceuticals, including anti-retroviral therapies, and markets its products in more than 165 countries and territories.